PMID- 30271881
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2397-575X (Print)
IS  - 2397-575X (Electronic)
IS  - 2397-575X (Linking)
VI  - 1
IP  - 2
DP  - 2016 Jun
TI  - B cell responses in older adults with latent tuberculosis: Considerations for 
      vaccine development.
PG  - 44-52
LID - 10.15761/GVI.1000112 [doi]
AB  - Reactivation of latent tuberculosis (LTBI) is more common among the aging 
      population and may contribute to increased transmission in long-term health care 
      facilities. Difficulties in detecting LTBI due to potential blunting of the 
      tuberculin skin test (TST), and the lowered ability of the elderly to tolerate 
      the course of antibiotics, underscore the need for an effective vaccine. 
      Immuno-senescence reduces the capacity of vaccines to induce sufficient levels of 
      protective immunity against many pathogens, further increasing the susceptibility 
      of the elderly to infectious diseases. We sought to evaluate the response of B 
      cells to Mycobacterium tuberculosis (Mtb) in residents of long-term care 
      facilities to determine the feasibility of using a vaccine to control infection 
      and transmission from reactivated LTBI. Our results demonstrate that although B 
      cell responses were higher in subjects with LTBI, Mtb antigens could stimulate B 
      cell activation and differentiation in vitro in TST negative subjects. B cells 
      from elderly subjects expressed high basal levels of Toll-like receptor (TLR)2 
      and TLR4 and responded strongly to Mtb ligands with some activation pathways 
      dependent on TLR2. B cells derived from blood, tonsil and spleen from younger 
      subjects responded similarly and to the same magnitude. These results suggest 
      that B cell responses are robust in the elderly and modifications to a TB 
      vaccine, such as TLR2 ligand-based adjuvants, may help increase immune responses 
      to a protective level.
FAU - Helbig, Sina
AU  - Helbig S
AD  - Section of Infectious Diseases, Boston University School of Medicine, Boston, MA, 
      USA.
FAU - Rekhtman, Sergey
AU  - Rekhtman S
AD  - Department of Epidemiology, Boston University School of Public Health, Boston, 
      MA, USA.
FAU - Dostie, Kristen
AU  - Dostie K
AD  - Center for International Health Research, Rhode Island Hospital, Providence, RI, 
      USA.
FAU - Casler, Alexander
AU  - Casler A
AD  - STC Biologics, Inc. Cambridge, MA, USA.
FAU - Schneider, Thomas
AU  - Schneider T
AD  - STC Biologics, Inc. Cambridge, MA, USA.
FAU - Hochberg, Natasha S
AU  - Hochberg NS
AD  - Section of Infectious Diseases, Boston University School of Medicine, Boston, MA, 
      USA.
AD  - Department of Epidemiology, Boston University School of Public Health, Boston, 
      MA, USA.
FAU - Ganley-Leal, Lisa
AU  - Ganley-Leal L
AD  - Section of Infectious Diseases, Boston University School of Medicine, Boston, MA, 
      USA.
AD  - Center for International Health Research, Rhode Island Hospital, Providence, RI, 
      USA.
AD  - STC Biologics, Inc. Cambridge, MA, USA.
LA  - eng
GR  - K12 HD043444/HD/NICHD NIH HHS/United States
GR  - R01 AI116593/AI/NIAID NIH HHS/United States
GR  - R21 AI097684/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20160527
PL  - England
TA  - Glob Vaccines Immunol
JT  - Global vaccines and immunology
JID - 101692536
PMC - PMC6159916
MID - NIHMS816183
EDAT- 2016/06/01 00:00
MHDA- 2016/06/01 00:01
PMCR- 2018/09/27
CRDT- 2018/10/02 06:00
PHST- 2018/10/02 06:00 [entrez]
PHST- 2016/06/01 00:00 [pubmed]
PHST- 2016/06/01 00:01 [medline]
PHST- 2018/09/27 00:00 [pmc-release]
AID - 10.15761/GVI.1000112 [doi]
PST - ppublish
SO  - Glob Vaccines Immunol. 2016 Jun;1(2):44-52. doi: 10.15761/GVI.1000112. Epub 2016 
      May 27.